- Home
- SILC vs KRRO Comparison
SILC vs KRRO Comparison
Compare SILC & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SILC | KRRO |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.3M | 101.1M |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SILC | KRRO |
|---|---|---|
| Price | $18.74 | $11.22 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 12 |
| Target Price | N/A | ★ $54.60 |
| AVG Volume (30 Days) | 81.2K | ★ 291.1K |
| Earning Date | 01-29-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $61,926,000.00 | $7,371,000.00 |
| Revenue This Year | $17.17 | $145.97 |
| Revenue Next Year | $12.28 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.56 | N/A |
| 52 Week Low | $12.44 | $5.20 |
| 52 Week High | $23.00 | $55.89 |
Technical Indicators
Market Signals| Indicator | SILC | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 54.35 | 54.35 |
| Support Level | $18.55 | $10.81 |
| Resistance Level | $21.22 | $12.46 |
| Average True Range (ATR) | 1.86 | 1.08 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 46.48 | 33.02 |
Price Performance
Historical ComparisonAbout SILC Silicom Ltd
Silicom Ltd designs and manufactures networking and data infrastructure solutions for various servers, server-based systems, and communications devices. Its product categories consist of Server Adapters, Edge Networking Solutions, FPGA-Based Cards, x86 Open Appliances, Bypass Switches, and TAPs. Geographically, it derives a majority of its revenue from North America and also has a presence in Europe and Asia-Pacific.
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.